The 36th National Congress on Respiratory Diseases has come to a close. Over four eventful days, pulmonologists, allergists, tuberculosis specialists, internal medicine physicians, pediatricians, oncologists, general practitioners, functional diagnostics specialists, and healthcare administrators from across Russia and other countries attended more than 200 events within the scientific program. Plenary sessions, symposia, clinical case marathons, workshops, roundtable discussions, poster sessions, and practical training courses provided healthcare professionals with opportunities to exchange experience and explore current treatment approaches, while stimulating research and innovation in respiratory medicine in response to real-world clinical challenges.
Having access to the medicines needed for treatment plays a key role in controlling symptoms, reducing the frequency of exacerbations, and maintaining quality of life for patients with chronic respiratory diseases. Ensuring access to modern, high-tech medicines for the treatment of chronic respiratory diseases in Russia is the primary focus of PSK Pharma's development strategy.
The Congress's scientific program featured presentations on clinical experience with Respirable, the first domestically developed dual bronchodilator, which PSK Pharma developed and launched on the Russian market in 2025. Over the course of a year, prescriptions for this Russian medicine, combining glycopyrronium bromide and indacaterol in a single-dose dry powder inhaler, have doubled.
«The fixed-dose combination of glycopyrronium and indacaterol represents a highly effective treatment option for patients with COPD,» emphasized Natalia Aleksandrovna Esaulova, MD, PhD, Head of Department at the Ural Research Institute of Phthisiopulmonaryology of the Russian Ministry of Health, highlighting the clinical relevance of the medicine in her presentation.
Congress participants noted PSK Pharma's high level of responsibility in developing its pharmaceutical products. In clinical trials, the company's import-substituting inhaled medicines have demonstrated therapeutic equivalence to reference international products, as well as comparable efficacy and safety.
One of the highlights of the 36th National Congress on Respiratory Diseases was the presentation of a novel therapy developed in Russia - a metered-dose dry powder inhaler containing a fixed-dose triple combination of glycopyrronium bromide, indacaterol, and ciclesonide. No medicines containing this combination of molecules are currently available anywhere in the world. This development marks a new stage in the evolution of PSK Pharma's respiratory portfolio, reflecting a strategic transition from import substitution to the development and introduction of its own innovative therapies.
How the Medical Community Views the New Russian Development: Expert Opinions
«Pharmaceutical security is extremely important. PSK Pharma, a Russian company, provides medicines covering virtually the entire spectrum of obstructive lung diseases. Triple-combination therapy is a highly relevant topic today. This is a truly advanced development», - Andrey Stanislavovich Belevsky, MD, DSc, Professor, President of the Russian Respiratory Society, Chief Pulmonology Specialist of the Moscow Department of Health, Head of the Department of Pulmonology at Pirogov Russian National Research Medical University, and Honored Physician of the Russian Federation
«PSK Pharma previously introduced a dual combination for COPD treatment. We are now looking forward to the triple combination, which will also be in demand and have a significant impact on the course of the disease in patients with bronchial asthma and COPD. It is particularly encouraging that this is a Russian company»,- Alexander Viktorovich Zhestkov, Acting Chief Pulmonology Specialist for the Volga Federal District.
«One of the encouraging developments in pharmaceutical provision over the past few years has been the growing presence of Russian pharmaceutical companies. Patients are satisfied with the effectiveness of their prescribed treatments. We can see that the Russian pharmaceutical industry continues to develop. We are already using the dual combination of glycopyrronium bromide and indacaterol and are very much looking forward to the Russian triple combination», - Gennady Ivanovich Mokhovikov, Chief Pulmonology Specialist of the Ministry of Health of the Republic of Karelia.
«I believe that not only we, the pulmonologists of Stavropol Krai and the North Caucasian Federal District, are looking forward to this combination, but our patients are also eagerly awaiting it», - Oksana Yuryevna Pozdnyakova, Chief General Practice Specialist of the North Caucasian Federal District, Chief Pulmonology Specialist of Stavropol Krai, and Board Member of the Russian Association of General Practitioners.
«It is good news to hear that PSK Pharma is developing a triple combination of bronchodilators with ciclesonide, one of the newest inhaled corticosteroids. This will certainly be a major breakthrough in pulmonology, not only in Russia but worldwide. I believe that the emergence of high-quality Russian medicines that meet the needs of the majority of our patients represents a very positive development in our pharmaceutical market», - Vasily Dmitrievich Fedotov, MD, PhD, Chief Pulmonology Specialist of the Ministry of Health of the Nizhny Novgorod Region.
«We expect further development of inhaled medicines containing ciclesonide. The transition from generic medicines to the creation of an original, proprietary medicine marks a new chapter. This is extremely important, and we are eagerly looking forward to it. It is a major step forward for the entire Russian pharmaceutical industry and the pulmonology community», - Vladimir Dmitrievich Beketov, Associate Professor at the Department of Internal Medicine, Occupational Diseases and Rheumatology, Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University); Pulmonologist, Internal Medicine Physician, Cardiologist, and Psychologist.
Experts from neighboring countries also highlighted the significant export potential of PSK Pharma's respiratory portfolio. The company currently holds more than 25 marketing authorizations across six foreign countries.
